drugset / Trial / NCT06971614

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

NCT06971614

Phase 2 Recruiting 160 enrolled ImmVira Pharma Co. Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.

Timeline

Start
2025-06-09
Primary completion
2028-12-31
Completion
2029-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject T3011 Other / unclassified 1e+10 unknown Other